This website is intended for healthcare professionals only.
Hospital Pharmacy Europe
Newsletter
Login
News
In depth
Views
Clinical
Cardiovascular
Dermatology
Emergency and critical care
Gastroenterology
Oncology
Paediatrics
Pathology and diagnostics
Radiology and imaging
Respiratory
Rheumatology
Insight and Analysis
Q&As
European healthcare data
Webinars
Country profiles
Events
Sponsored
Newsletter
Hospital Pharmacy Europe
Dermatology
RCT finds tralokinumab effective in adolescents with atopic eczema
Read more
Bimekizumab shows promise in hidradenitis suppurativa
Read more
Enhanced vs reactive treatment of atopic eczema reduces hen egg allergy
Read more
Lebrikizumab monotherapy effective in moderate to severe atopic eczema
Read more
Dupilumab treatment improves spontaneous chronic urticaria activity and quality of life
Read more
Adherence to NICE criteria for biologic treatment in atopic dermatitis
Read more
Dupixent approved for severe atopic dermatitis in children from 6 months
Read more
Lebrikizumab and topical steroids effective in moderate to severe atopic eczema
Read more
Early emollient use among high-risk infants prevents atopic eczema
Read more
Dupixent recommended for EU approval to treat moderate to severe prurigo nodularis
Read more
Topical ruxolitinib effective in non-segmental vitiligo
Read more
RCT finds dupilumab effective for children under six with atopic eczema
Read more
Sun awareness measures failing to alter behaviour
Read more
Basal cell carcinoma diagnosis improved with novel imaging technique
Read more
FDA approves ruxolitinib cream for vitiligo
Read more
Stopping methotrexate for 2 weeks after COVID-19 vaccination boosts immune response
Read more
Green tea extract decreases severity of radiation-induced dermatitis in breast cancer patients
Read more
Page 3 of 7
«
1
2
3
4
5
...
»
Last »
Popular articles
New protocol for IBD referral triage reduces diagnostic delays, say researchers
24 April, 2024
Ivacaftor use in cystic fibrosis ‘safe and effective’ from one month old, study finds
25 April, 2024
Semaglutide shows promise in patients with type 2 diabetes and obesity-related heart failure
22 April, 2024
x
Search for: